Trials / NCT01521793
Repeated Treatments of QLT091001 in Subjects With Leber Congenital Amaurosis or Retinitis Pigmentosa (Extension of Study RET IRD 01)
Completed Phase 1 Drug / neuroprotection
- Sponsor
- QLT Inc.
- Treatment
- QLT091001
- Gene
- RPE65
- Conditions
- LCA (Leber Congenital Amaurosis), RP (Retinitis Pigmentosa)
- Ages
- 5 Years to 65 Years
- Enrollment
- 27 participants
- Started
- 2012-01
- Main results expected
- 2014-05
- Results posted
- Not yet
- Record last updated
- 2014-07-28
What the study is testing
The purpose of this study is:
- To evaluate the safety of up to 3 additional courses of oral QLT091001 administered once daily for 7 days in subjects treated previously with a single 7-day course of QLT091001 in Study RET IRD 01
- To evaluate whether up to 3 additional courses of oral QLT091001 administered once daily for 7 days can maintain or improve visual function.
Where it runs
Canada (1)
- Montreal Children's Hospital, McGill University Health Centre, Montreal, Quebec
Germany (1)
- Institute for Ophthalmic Research, University of Tubingen, Tübingen
Netherlands (1)
- The Rotterdam Eye Hospital, Rotterdam
United Kingdom (1)
- Moorefield Eye Hospital, London
United States (2)
- The Chicago Lighthouse (University of Illinois at Chicago, Pangere Center for Inherited Retinal Disease), Chicago, Illinois
- Wilmer Eye Institute (Johns Hopkins University), Baltimore, Maryland